Westwood Alice C, Wilson Benjamin I, Laye Jon, Grabsch Heike I, Mueller Wolfram, Magee Derek R, Quirke Phillip, West Nicholas P
Division of Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
School of Computing, University of Leeds, Leeds, UK.
BJC Rep. 2025 Mar 3;3(1):12. doi: 10.1038/s44276-025-00123-8.
Within the colorectal cancer (CRC) tumour microenvironment, tumour infiltrating lymphocytes (TILs) and tumour cell density (TCD) are recognised prognostic markers. Measurement of TILs and TCD using deep-learning (DL) on haematoxylin and eosin (HE) whole slide images (WSIs) could aid management.
HE WSIs from the primary tumours of 127 CRC patients were included. DL was used to quantify TILs across different regions of the tumour and TCD at the luminal surface. The relationship between TILs, TCD, and cancer-specific survival was analysed.
Median TIL density was higher at the invasive margin than the luminal surface (963 vs 795 TILs/mm, P = 0.010). TILs and TCD were independently prognostic in multivariate analyses (HR 4.28, 95% CI 1.87-11.71, P = 0.004; HR 2.72, 95% CI 1.19-6.17, P = 0.017, respectively). Patients with both low TCD and low TILs had the poorest survival (HR 10.0, 95% CI 2.51-39.78, P = 0.001), when compared to those with a high TCD and TILs score.
DL derived TIL and TCD score were independently prognostic in CRC. Patients with low TILs and TCD are at the highest risk of cancer-specific death. DL quantification of TILs and TCD could be used in combination alongside other validated prognostic biomarkers in routine clinical practice.
在结直肠癌(CRC)肿瘤微环境中,肿瘤浸润淋巴细胞(TILs)和肿瘤细胞密度(TCD)是公认的预后标志物。利用深度学习(DL)对苏木精和伊红(HE)全切片图像(WSIs)进行TILs和TCD的测量有助于治疗管理。
纳入127例CRC患者原发肿瘤的HE WSIs。采用DL对肿瘤不同区域的TILs及腔面的TCD进行定量分析。分析TILs、TCD与癌症特异性生存之间的关系。
浸润边缘的TIL密度中位数高于腔面(963对795个TILs/mm,P = 0.010)。在多变量分析中,TILs和TCD具有独立的预后价值(HR分别为4.28,95%CI 1.87 - 11.71,P = 0.004;HR为2.72,95%CI 1.19 - 6.17,P = 0.017)。与TCD和TILs评分高的患者相比,TCD和TILs均低的患者生存率最差(HR 10.0,95%CI 2.51 - 39.78,P = 0.001)。
DL得出的TIL和TCD评分在CRC中具有独立的预后价值。TILs和TCD低的患者癌症特异性死亡风险最高。DL对TILs和TCD的定量可在常规临床实践中与其他经过验证的预后生物标志物联合使用。